Magellan Bioscience Group
1
15M
1
0.04
1
- Areas of investment
Summary
Magellan Bioscience Group appeared to be the Corporate Investor, which was created in 1997. The fund was located in North America if to be more exact in United States. The main office of represented Corporate Investor is situated in the Tampa.
The fund is generally included in less than 2 deals every year. The important activity for fund was in 2005. The increased amount of exits for fund were in 2008. The common things for fund are deals in the range of 10 - 50 millions dollars.
The standard case for the fund is to invest in rounds with 3 partakers. Despite the Magellan Bioscience Group, startups are often financed by Guidant. The meaningful sponsors for the fund in investment in the same round are BioMedPartners, Advent-Morro Equity Partners. In the next rounds fund is usually obtained by Rogers Communications.
For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline Bioheart Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most successful fund investment fields, there are Developer Platform, Therapeutics.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.04
- Investments by industry
- Therapeutics (1)
- Biotechnology (1)
- Health Care (1)
- Developer Platform (1)
- Medical (1) Show 1 more
- Investments by region
-
- United States (1)
- Peak activity year
- 2005
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 22
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.